All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During SOHO 2019 in Houston, US, Dr Jennifer A. Woyach from The Ohio State University (OSUCCC) in Columbus, US, spoke to the Lymphoma Hub about novel targeted therapies for chronic lymphocytic leukemia (CLL) treatment. She gives an overview of small molecule inhibitors of BTK in clinical development, other than ibrutinib, and venetoclax. Those include new covalent and reversible inhibitors, which are more selective and therefore associated with less toxicity but are also able to overcome ibrutinib resistance.
Beyond ibrutinib and venetoclax, what are other novel targeted therapies for CLL treatment?
Management of patients with CLL after venetoclax discontinuation
Results from a study addressing the optimal treatment regimen after discontinuation of venetoclax and the impact of venetoclax resistance on the efficacy of subsequent therapies.
Educational theme: Improving front-line treatment in CLL
The educational theme article focusing on the front-line treatment of chronic lymphocytic leukemia (CLL).
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox